{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:01:52Z","timestamp":1740106912348,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00277-022-04807-w","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T03:02:26Z","timestamp":1646708546000},"page":"1239-1250","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dynamic change in peripheral blood WT1 mRNA levels within three cycles of azacitidine predict treatment response in patients with high-risk myelodysplastic syndromes"],"prefix":"10.1007","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3592-9066","authenticated-orcid":false,"given":"Shinpei","family":"Harada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Onozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Senjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiki","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Kanaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,8]]},"reference":[{"issue":"20","key":"4807_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405","journal-title":"Blood"},{"issue":"12","key":"4807_CR2","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J et al (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12):2454\u20132465","journal-title":"Blood"},{"issue":"3","key":"4807_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10(3):223\u2013232","journal-title":"Lancet Oncol"},{"issue":"12","key":"4807_CR4","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1002\/cncr.25774","volume":"117","author":"LR Silverman","year":"2011","unstructured":"Silverman LR, Fenaux P, Mufti GJ et al (2011) Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 117(12):2697\u20132702","journal-title":"Cancer"},{"issue":"7","key":"4807_CR5","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3324\/haematol.2012.074831","volume":"98","author":"SD Gore","year":"2013","unstructured":"Gore SD, Fenaux P, Santini V et al (2013) A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacytidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 98(7):1067\u20131072","journal-title":"Haematologica"},{"issue":"3","key":"4807_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/sj.leu.2401341","volume":"13","author":"T Tamaki","year":"1999","unstructured":"Tamaki T, Ogawa H, Ohyashiki K et al (1999) The Wilms\u2019 tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 13(3):393\u2013399","journal-title":"Leukemia"},{"issue":"7","key":"4807_CR7","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3109\/10428194.2012.745074","volume":"54","author":"Y Ueda","year":"2013","unstructured":"Ueda Y, Mizutani C, Nannya Y et al (2013) Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. Leuk Lymphoma 54(7):1450\u20131458","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"4807_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41408-019-0248-y","volume":"9","author":"C Rautenberg","year":"2019","unstructured":"Rautenberg C, Germing U, Pechtel S et al (2019) Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS. Blood Cancer J 9(11):20\u201386","journal-title":"Blood Cancer J"},{"issue":"8","key":"4807_CR9","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.leukres.2009.11.029","volume":"34","author":"H Tamura","year":"2010","unstructured":"Tamura H, Dan K, Yokose N et al (2010) Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes. Leuk Res 34(8):986\u2013990","journal-title":"Leuk Res"},{"issue":"1","key":"4807_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3233\/CBM-160612","volume":"17","author":"S Kobayashi","year":"2016","unstructured":"Kobayashi S, Ueda Y, Nannya Y et al (2016) Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. Cancer Biomark 17(1):21\u201332","journal-title":"Cancer Biomark"},{"issue":"1","key":"4807_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000452732","volume":"137","author":"J Nagasaki","year":"2017","unstructured":"Nagasaki J, Aoyama Y, Hino M et al (2017) Wilms Tumor 1 (WT1) mRNA expression level at diagnosis is a significant prognostic marker in elderly patients with myelodysplastic syndrome. Acta Haematol 137(1):32\u201339","journal-title":"Acta Haematol"},{"issue":"10","key":"4807_CR12","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1200\/JCO.2003.10.503","volume":"21","author":"D Cilloni","year":"2003","unstructured":"Cilloni D, Gottardi E, Messa F et al (2003) Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 21(10):1988\u20131995","journal-title":"J Clin Oncol"},{"issue":"4","key":"4807_CR13","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.leukres.2010.08.021","volume":"35","author":"G Alimena","year":"2011","unstructured":"Alimena G, Breccia M, Musto P et al (2011) Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes. Leuk Res 35(4):504\u2013507","journal-title":"Leuk Res"},{"issue":"3","key":"4807_CR14","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/bjh.15098","volume":"184","author":"X Du","year":"2019","unstructured":"Du X, Geng S, Weng J et al (2019) WT1 mRNA level reflects disease changes and progression of myelodysplastic syndromes patients with \u2018stable disease.\u2019 Br J Haematol 184(3):447\u2013450","journal-title":"Br J Haematol"},{"issue":"3","key":"4807_CR15","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/ejh.13275","volume":"103","author":"M Santaliestra","year":"2019","unstructured":"Santaliestra M, Garrido A, Carricondo M et al (2019) Bone marrow WT1 levels in patients with myeloid neoplasms treated with 5-azacytidine: identification of responding patients. Eur J Haematol 103(3):208\u2013214","journal-title":"Eur J Haematol"},{"issue":"7","key":"4807_CR16","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1182\/blood-2016-02-700054","volume":"128","author":"M Pfeilst\u00f6cker","year":"2016","unstructured":"Pfeilst\u00f6cker M, Tuechler H, Sanz G et al (2016) Time-dependent changes in mortality and transformation risk in MDS. Blood 128(7):902\u2013910","journal-title":"Blood"},{"issue":"10","key":"4807_CR17","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.3109\/10428194.2010.507829","volume":"51","author":"N Miyawaki","year":"2010","unstructured":"Miyawaki N, Hatsumi T, Tamaki T et al (2010) Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia. Leuk Lymphoma 51(10):1855\u20131861","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"4807_CR18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennett JM et al (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108(2):419\u2013425","journal-title":"Blood"},{"issue":"3","key":"4807_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"4807_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1756-8722-4-46","volume":"4","author":"G Wei","year":"2011","unstructured":"Wei G, Ni W, Chiao JW et al (2011) A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol 4:46","journal-title":"J Hematol Oncol"},{"issue":"10","key":"4807_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.tig.2012.04.004","volume":"28","author":"YY Chau","year":"2012","unstructured":"Chau YY, Hastie ND (2012) The role of Wt1 in regulating mesenchyme in cancer, development, and tissue homeostasis. Trends Genet 28(10):515\u2013524","journal-title":"Trends Genet"},{"issue":"8","key":"4807_CR22","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/sj.leu.2404752","volume":"21","author":"N Hosen","year":"2007","unstructured":"Hosen N, Shirakata T, Nishida S et al (2007) The Wilms\u2019 tumor gene WT1-GEP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis. Leukemia 21(8):1783\u20131791","journal-title":"Leukemia"},{"issue":"9","key":"4807_CR23","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1182\/blood.V84.9.3071.3071","volume":"84","author":"K Inoue","year":"1994","unstructured":"Inoue K, Sugiyama H, Ogawa H et al (1994) WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84(9):3071\u20133079","journal-title":"Blood"},{"issue":"12","key":"4807_CR24","first-page":"1279","volume":"46","author":"S Miyawaki","year":"2005","unstructured":"Miyawaki S, Emi N, Mitani K et al (2005) Clinical course of the disease and the level of WT1 mRNA in patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan. Jpn J Clin Hematol 46(12):1279\u20131287","journal-title":"Jpn J Clin Hematol"},{"issue":"11","key":"4807_CR25","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1016\/j.clml.2018.07.291","volume":"18","author":"D Hidaka","year":"2018","unstructured":"Hidaka D, Onozawa M, Hashiguchi J et al (2018) Wilms tumor 1 expression at diagnosis correlates with genetic abnormalities and polymorphism but is not independently prognostic in acute myelogenous leukemia: a Hokkaido Leukemia Net study. Clin Lymphoma Myeloma Leuk 18(11):e469\u2013e479","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"4807_CR26","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1182\/blood.V88.6.2267.bloodjournal8862267","volume":"88","author":"K Inoue","year":"1996","unstructured":"Inoue K, Ogawa H, Yamaguchi T et al (1996) Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 88(6):2267\u20132278","journal-title":"Blood"},{"issue":"31","key":"4807_CR27","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1200\/JCO.2009.22.4865","volume":"27","author":"D Cillioni","year":"2009","unstructured":"Cillioni D, Renneville A, Hermitte F et al (2009) Real-time quantative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukimiaNet study. J Clin Oncol 27(31):5195\u20135201","journal-title":"J Clin Oncol"},{"issue":"11","key":"4807_CR28","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.bbmt.2018.05.011","volume":"24","author":"C Rautenberg","year":"2018","unstructured":"Rautenberg C, Pechtel S, Hildebrandt B et al (2018) Wilms\u2019 tumor 1 gene expression using a standardized European LeukemiaNet-certified assay compared to other methods for detection of minimal residual disease in myelodysplastic syndrome and acute myelogenous leukemia after allogeneic blood stem cell transplantation. Biol Blood Marrow Transplant 24(11):2337\u20132343","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"4807_CR29","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/leu.2010.283","volume":"25","author":"T Lange","year":"2011","unstructured":"Lange T, Hubmann M, Burkhardt R et al (2011) Monitoring of WT1 expression in PB and CD34 donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia 25(3):498\u2013505","journal-title":"Leukemia"},{"issue":"2","key":"4807_CR30","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41409-020-01039-2","volume":"56","author":"C Rautenberg","year":"2020","unstructured":"Rautenberg C, Bergmann A, Pechtel S et al (2020) Wilm\u2019s tumor 1-guided preemptive treatment with hypomethylating agents for molecular relapse of AML and MDS after allogeneic transplantation. Bone Marrow Transplant 56(2):442\u2013450","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"4807_CR31","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1111\/cas.13739","volume":"109","author":"Y Morita","year":"2018","unstructured":"Morita Y, Maeda Y, Yamaguchi T et al (2018) Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): a prospective single-arm phase 2 trial. Cancer Sci 109(10):3209\u20133215","journal-title":"Cancer Sci"},{"issue":"21","key":"4807_CR32","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","volume":"375","author":"JS Welch","year":"2016","unstructured":"Welch JS, Petti AA, Miller CA et al (2016) TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med 375(21):2023\u20132036","journal-title":"N Engl J Med"},{"issue":"4","key":"4807_CR33","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/bjh.14455","volume":"176","author":"CK Chang","year":"2017","unstructured":"Chang CK, Zhao YS, Xu F et al (2017) TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes. Br J Haematol 176(4):600\u2013608","journal-title":"Br J Haematol"},{"issue":"1","key":"4807_CR34","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1038\/s41598-020-76510-7","volume":"10","author":"K Kim","year":"2020","unstructured":"Kim K, Park S, Choi H et al (2020) Gene expression signatures associated with sensitivity to azacitidine in myelodysplastic syndromes. Sci Rep 10(1):19555","journal-title":"Sci Rep"},{"issue":"3","key":"4807_CR35","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00277-020-03932-8","volume":"99","author":"I Martin","year":"2020","unstructured":"Martin I, Navarro B, Serrano A et al (2020) Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine. Ann Hematol 99(3):527\u2013537","journal-title":"Ann Hematol"},{"issue":"4","key":"4807_CR36","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.clml.2014.10.003","volume":"15","author":"JF Falantes","year":"2015","unstructured":"Falantes JF, Trujillo P, Piruat JI et al (2015) Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 15(4):236\u2013244","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04807-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04807-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04807-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T10:08:53Z","timestamp":1651745333000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04807-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,8]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["4807"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04807-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2022,3,8]]},"assertion":[{"value":"14 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.T. has received research funding from Nippon Shinyaku. The other authors report no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the institutional review board of Aiiku Hospital and Sapporo Hokuyu Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}